Pradaxa 150 milligram overtrukket granulat; forsyningsvanskelighed
Safety Classified by Officially
Markedsføringen af Pradaxa 150 mg overtrukket granulat fra Boehringer Ingelheim Danmark A/S vil ophøre.
Produkt: Pradaxa 150 mg overtrukket granulat
Aktivt stof: Dabigatranetexilat (Dabigatranetexilatmesilat)
Forventet periode: Fra slut november 2026
Virksomhed: Boehringer Ingelheim Danmark A/S
Yderligere information: Permanent markedsophør
This is an extract. The publication continues at the source.
Source: Lægemiddelstyrelsen.
Read the original at the source: https://laegemiddelstyrelsen.dk/da/godkendelse/kontrol-og-inspektion/mangel-paa-medicin/meddelelser-om-forsyning-af-medicin/human-2026/pradaxa-150-milligram-overtrukket-granulat-forsyningsvanskelighed/
Officially imported this from Lægemiddelstyrelsen’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
This publication has changed since it was first published
2 versions recorded. The original is kept in full — nothing is overwritten.
- v2 imported change on current
- v1 as first published on Titled: “Pradaxa 150 mg overtrukket granulat: forsyningsvanskelighed”
Provenance
- Organization
- Lægemiddelstyrelsen — imported from official source
- Official source
- https://laegemiddelstyrelsen.dk/da/Feeds/rss-feed/ RSS
- Imported
- October 03, 2026 20:38
- Versions
- 2 recorded
- Identity
-
900BAFFB09A7433E9276E77A1890D1D5